What is Ganciclovir (Cytovene and Cymevene)?
Ganciclovir is a synthetic nucleoside analogue of guanine closely related to aciclovir. Ganciclovir is an antiviral medication used to treat or prevent cytomegalovirus (CMV) infections. Ganciclovir sodium is marketed under the trade names Cytovene and Cymevene (Roche). Ganciclovir for ocular use is marketed under the trade name Vitrasert (Bausch & Lomb). A prodrug form with improved oral bioavailability (valganciclovir) has also been developed.
Indication/Contraindication for use of Ganciclovir (Cytovene and Cymevene)
- Hypersensitivity absolute neutrophil count below 500 cells/mm3; platelet count below 25,000/ mm3 ; pregnancy and lactation.
- Treatment & suppression of life threatening or slight threatening cytomegalovirus infections in immuno compromised patients, including those with AIDS and those with iatrogenic immunosuppression associated with organ transplantation or chemo therapy of neoplastic disease.
- Not to be administered as a bolus injection.
Side Effects of Ganciclovir (Cytovene and Cymevene)
- Haematolgical disturbances; marrow depression; GI disturbances; fever, rash and abnormal liver function tests; irritation and phioebitis at injection site.
- Potential risk of testicular effects and female fertility
- Less frequent: metabolic, musculus skeletal, respiratory, urogenital ocular effects, cutaneous symptoms and increased serum creatinine and BUN concentration
Dosage and Prescribing Information for Ganciclovir (Cytovene and Cymevene)
For immune compromised and advanced HIV patients: 1 g tid with food.
Drug Interactions of Ganciclovir (Cytovene and Cymevene)
Renal clearance reduced by probenecid; implementation’s (generalized seizures); zidovudine;didanosine; additive toxic effects with myelo suppressants; oral mycophenolate mofetil.
Precautions while prescribing Ganciclovir (Cytovene and Cymevene)
- Avoid contact with the skin and eyes impairment; preexisting cytopaenias or history of cytopaenic reactions to drugs; child: contraceptive precautions to be followed during and at least 90 days thereafter; care in administering only into veins with good blood flow.